Holen Sie sich die Stockscreener-App
1.71
28.57%
0.38
Handel nachbörslich:
1.66
-0.05
-2.92%
Cabaletta Bio Inc Aktie (CABA) Neueste Nachrichten
Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Bought by Federated Hermes Inc. - MarketBeat
CABA.O Spikes Sharply—Was It a KDJ Golden Cross or Broader Biotech Rotation? - AInvest
What makes Cabaletta Bio Inc. stock price move sharplyPrice Volume Breakout Screener - thegnnews.com
Cabaletta Bio shares fall 1.84% intraday due to lock-up agreements on stock options and warrants. - AInvest
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why - Yahoo Finance
Vinay Prasad's Comeback To FDA Sparks Debate Over Regulatory Direction - Benzinga
Are Bears Losing Grip on Cabaletta Bio Inc.Real-Time Market Sentiment Tracking Gains Momentum - beatles.ru
Cabaletta Bio shares rise 4.41% premarket as stock options lock-up agreement ends. - AInvest
Certain Stock Options of Cabaletta Bio, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-2025. - MarketScreener
Certain Common Stock of Cabaletta Bio, Inc. are subject to a Lock-Up Agreement Ending on 11-AUG-2025. - MarketScreener
Cabaletta Bio (CABA) Projected to Post Earnings on Thursday - MarketBeat
Cabaletta Bio, Inc. (NASDAQ:CABA) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Cabaletta Bio Advances Rese-cel Pipeline as BLA Submission for Myositis Nears - MSN
Wells Fargo Adjusts Price Target for Cabaletta Bio to $2.00, Reflecting a 33.33% Decrease from $3.00. - AInvest
Guggenheim lowers Cabaletta Bio stock price target to $15 on dilution - Investing.com Canada
Cabaletta Bio Reports Progress in Clinical Trials - TipRanks
Jefferies lowers Cabaletta Bio stock price target to $14 from $28 - Investing.com
Cabaletta Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 - MarketScreener
Cabaletta Bio (CABA) Plans $240M Mixed Securities Offering - GuruFocus
Cabaletta Bio Files $240 Million Shelf Offering - MarketScreener
Cabaletta Bio Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Cabaletta Bio’s Promising Clinical Study on CABA-201 for Myasthenia Gravis - TipRanks
Cabaletta Bio (CABA) Q2 Loss Widens 30% - The Globe and Mail
Cabaletta Bio Inc files for mixed shelf offering of up to $240 million- SEC filing - MarketScreener
Cabaletta Bio Q2 2025: RESET-Myositis trial enrollment to start in 2H25, BLA submission in 2027. - AInvest
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update | CABA Stock News - GuruFocus
Cabaletta Bio Reports Second Quarter 2025 Financial Results and Provides Business Update - Yahoo Finance
Cabaletta Bio’s Promising Study on CABA-201 for Myasthenia Gravis: A Potential Game-Changer - TipRanks
Individual investors who have a significant stake must be disappointed along with institutions after Cabaletta Bio, Inc.'s (NASDAQ:CABA) market cap dropped by US$17m - Yahoo Finance
Cabaletta Bio Inc expected to post a loss of 65 cents a shareEarnings Preview - TradingView
Published on: 2025-08-04 17:06:26 - beatles.ru
How does Cabaletta Bio Inc. compare to its industry peersUnlock expert market analysis instantly - Jammu Links News
What institutional investors are buying Cabaletta Bio Inc. stockRapidly expanding wealth - Jammu Links News
How does Cabaletta Bio Inc. generate profit in a changing economyInvest smarter with actionable trading signals - Jammu Links News
What analysts say about Cabaletta Bio Inc. stockAchieve remarkable returns with smart investing - Jammu Links News
Should I hold or sell Cabaletta Bio Inc. stock in 2025Sky-high return potential - Jammu Links News
What is the dividend policy of Cabaletta Bio Inc. stockTurn market volatility into profit opportunities - Jammu Links News
What drives Cabaletta Bio Inc. stock priceUnlock powerful market trend analysis - Jammu Links News
How volatile is Cabaletta Bio Inc. stock compared to the marketConsistently exceptional gains - Jammu Links News
When is Cabaletta Bio Inc. stock expected to show significant growthBreakthrough financial growth - Jammu Links News
Cabaletta Bio Inc. Stock Analysis and ForecastGet ahead with breakthrough trading ideas - Jammu Links News
What catalysts could drive Cabaletta Bio Inc. stock higher in 2025High-performance investment picks - Jammu Links News
Is Cabaletta Bio Inc. a growth stock or a value stockMaximize returns with strategic stock selection - Jammu Links News
What is Cabaletta Bio Inc. company’s growth strategyCapitalize on fast-moving market trends - Jammu Links News
What are Cabaletta Bio Inc. company’s key revenue driversBuild wealth faster with consistent investment plans - Jammu Links News
What is the risk reward ratio of investing in Cabaletta Bio Inc. stockStock Strategy Trend Scanner For Every Investor - Jammu Links News
What’s the recovery path for long term holders of Cabaletta Bio Inc.Multi-Bagger Potential Stock Forecast Tools Released - metal.it
Is it the right time to buy Cabaletta Bio Inc. stockStock Strategy Tracker For Every Investor - Jammu Links News
Cabaletta Bio Inc. Company’s Quarterly Earnings Growth: What the Numbers SayDaily Chart Pattern Stock Forecast Shows Bullish Setup - metal.it
Why Cabaletta Bio Inc. stock attracts strong analyst attentionExit Ready Momentum Stock Watchlist Expanded - metal.it
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):